Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial
Authors not listed
University of California, Los Angeles · 2026
Abstract
In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients.
RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease.
In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Anonymous. (2026). Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial. <em>University of California, Los Angeles</em>. https://clinicaltrials.gov/study/NCT07469475
Vancouver
Anonymous. Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial. University of California, Los Angeles. 2026.
BibTeX
@misc{anon2026Effect,
title = {Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial},
author = {Anonymous},
journal = {University of California, Los Angeles},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of California, Los Angeles 2023
Open access · US-GOV
The Effect of Daily COMP-4 Supplementation on Brachial Artery Flow Mediated Dilation and Cellular Senescence Markers in Young and Healthy Individuals
SLEEP 2016
Open access · OA
Insomnia and Telomere Length in Older Adults
Oxidative Medicine and Cellular Longevity 2015
Open access · CC-BY
The Protective Effect of Lipoic Acid on Selected Cardiovascular Diseases Caused by Age-Related Oxidative Stress
University of Colorado, Denver 2024
Open access · US-GOV
Cardiometabolic Consequences of the Loss of Ovarian Function
Frontiers in Cell and Developmental Biology 2019
Open access · CC-BY
Pleiotropic Effects of mTOR and Autophagy During Development and Aging
Taichung Veterans General Hospital 2012
Open access · US-GOV